Literature DB >> 21312094

[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].

Franz Payer1.   

Abstract

This methodological paper on magnetic resonance tomography imaging recalls the assessment criteria on therapy response of Glioblastoma multiforme as defined by David Macdonald in 1990 that have remained State of the Art since their first publication. It defines the terms "pseudoprogression", "radiation induced necrosis" and "pseudoresponse". These phenomena are seen increasingly since the introduction of radiochemotherapy with Temozolomide as treatment standard in glioblastoma and since the use of antiangiogenetic therapy in malignant gliomas. Therefore, the assessment criteria have been recently updated with the newly proposed "RANO criteria (Response assessment in Neuro-Oncology)". Furthermore, the potential of additional information to conventional MR by MR perfusion, MR diffusion and MR spectroscopy is briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21312094     DOI: 10.1007/s10354-010-0860-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  22 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Authors:  Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

3.  Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Authors:  L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-04       Impact factor: 3.825

4.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

5.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.

Authors:  Christina Tsien; Craig J Galbán; Thomas L Chenevert; Timothy D Johnson; Daniel A Hamstra; Pia C Sundgren; Larry Junck; Charles R Meyer; Alnawaz Rehemtulla; Theodore Lawrence; Brian D Ross
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

Review 6.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Authors:  Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Journal:  BMC Cancer       Date:  2009-12-16       Impact factor: 4.430

Review 7.  Pseudoprogression and pseudoresponse in the treatment of gliomas.

Authors:  Dieta Brandsma; Martin J van den Bent
Journal:  Curr Opin Neurol       Date:  2009-12       Impact factor: 5.710

8.  End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Authors:  Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.

Authors:  Jeremy D Ruben; Michael Dally; Michael Bailey; Robin Smith; Catriona A McLean; Pasqual Fedele
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-06       Impact factor: 7.038

10.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.